ArriVent BioPharma, Inc. AVBP Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s accrued liabilities, current?
- ArriVent BioPharma, Inc. (AVBP) reported accrued liabilities, current of $16.17M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s accrued liabilities, current changed year-over-year?
- ArriVent BioPharma, Inc.'s accrued liabilities, current increased by 91.3% year-over-year, from $8.45M to $16.17M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s accrued liabilities, current?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s accrued liabilities, current has grown at a 69.6% compound annual growth rate (CAGR), from $6.95M to $20M.